Gemcitabine HCl

製品コードS1149 別名:LY188011

Gemcitabine HCl化学構造


Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

サイズ 価格(税別)  
JPY 11620.00
JPY 34860.00


  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine HCl purchased from Selleck.

    Analysis of CD31-positive staining in EMT-6 tumour treated with anti-CTLA-4 therapies. (A)EMT-6/P tumours were implanted s.c. into female Balb/c mice. Tumour bearing mice were treated with (i.e. a repeat of the experiment shown in Figure 2) saline control, CTLA-4, metronomic CTX (ld CTX), gemcitabine (Gem), or CTLA-4 plus ld CTX, or CTLA-4 with sequential Gemcitabine. The experiment was terminated as the tumours were starting to respond to the different therapies, as assessed by caliper measurements. Tumours were resected, fixed, and then paraffin embedded, and 5μ sections were then stained (brown) for CD31 (black bar=100 μ). (B) Image analysis of × 20 pictures of CD31 immunohistochemistry of tumour tissues from control- and drug-treated groups of mice. The quantification of the images was performed by the image analysis software ImageJ (Image Processing and Analysis in Java; Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, MD, USA) and the results are shown as the ratio between the CD31-positive area and the total area of the image. A one-way ANOVA analysis followed by Bartlett’s post test was applied to the results to demonstrate significant differences among the treatment groups. The statistical analysis of the data was performed with GraphPad Prism v.5.0. Blue lines, mean±s.d.; *P<0.05 vs control group.

    Br J Cancer, 2017, 116(3):324-334. Gemcitabine HCl purchased from Selleck.


    Injection of low-dose GEM suppresses tumor growth in vivo. BALB/c mice were injected s.c. with 5x 10^5 CT26 cells into the right flank. On day 10, mice were injected i.p. with GEM (50 or 100 mg/kg). Arrows indicate the injection of GEM. Tumor size(mm2) was measured twice weekly. Each group consisted of five or six mice, and lines represent tumor growth in each mouse. The mean ± SD of the results on day 30 after tumor inoculation are also shown. Similar results were obtained in two experiments. *P\0.05 indicates statistical significance by ANOVA with Dunnett’s post hoc test. NS, not significant.

    Cancer Immunol Immunother 2013 62, 383–391. Gemcitabine HCl purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48 h. Cell survival was measured by a standarad MTT assay.



    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine HCl purchased from Selleck.


DNA/RNA Synthesis阻害剤の選択性比較


製品説明 Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.
特性 Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
DNA synthesis (Capan2 cells) [1] DNA synthesis (BxPC3 cells) [1] DNA synthesis (MIAPaCa2 cells) [1] DNA synthesis (PANC1 cells) [1]
12 nM 18 nM 40 nM 50 nM

Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-κB binding. In contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h; however, 24-h treatment with these higher doses increases NF-κB binding in BxPC-3 cells [2]

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CCRF-CEM/dCK−/− M3K0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fXSmlEPTB;MkSwMlQhyrFiMkmuNEDPxE1? NGDsXGgzOjR{NUi4OS=>
L1210 wt M2XRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn63TWM2OD1zLkOgxtEhOC5|IH7N M3PFOVIzPDJ3OEi1
L1210 10K MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnPTXhSUUN3ME2yNk4zKMLzIEOuO{DPxE1? Ml\nNlI1OjV6OEW=
TC-1  NWDHW29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PFeWlEPTB;MUSuO{DDuSB{Lkigcm0> MWiyNlQzPTh6NR?=
TC-1-GR NYi4dpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6WnNKSzVyPUO2MlchyrFiNT6xJO69VQ>? MlTXNlI1OjV6OEW=
MIA PaCa-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nERWlEPTB;NEmuO{DDuSBzNz63JI5O NXnzcm1SOjJ2MkW4PFU>
PANC-1 M4XGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXne4JbUUN3ME2+JFQxOCEQvF2= M4O0eVIzPDJ3OEi1
CCRF-CEM MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJwOTFCtUAyNjhibl2= NFnBUoszOjR{NUi4OS=>
CCRF-CEM-AraC-8C MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1riW2lEPTB;OUm4MlghyrFiOT60JI5O NV;LdYVUOjJ2MkW4PFU>
CCRF-CEM  MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjETFE4OiCq M1frRWlEPTB;Mj6wJOKyKDBwNjDuUS=> MX:yNVg2OTh2Mx?=


体内試験 Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-κB activation. [2]


細胞試験: [2]
+ 展開
  • 細胞株: BxPC-3, MIA PaCa-2, and PANC-1 cells
  • 濃度: 0.2 μM
  • 反応時間: 24 hours or 48 hours
  • 実験の流れ: BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells.
+ 展開
  • 動物モデル: Athymic nude mice with MIA PaCa-2 cells
  • 製剤: Phosphate-buffered saline
  • 投薬量: 50 mg/kg or 100 mg/kg
  • 投与方法: Administered via i.p.

溶解度 (25°C)

体外 Water 19 mg/mL (63.4 mM)
DMSO Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。


分子量 299.66


CAS No. 122111-03-9
in solvent
別名 LY188011





質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)


  • 質量





開始濃度 x 開始体積 = 最終濃度 x 最終体積


この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1



  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):




チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2


質量 濃度 体積 分子量


NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03737123 Not yet recruiting Urothelial Carcinoma Nabil Adra|Genentech Inc.|Hoosier Cancer Research Network January 2019 Phase 2



Handling Instructions


  • * 必須


  • 質問1:

    What’s the difference between S1714 and S1149 and which one is better?

  • 回答:

    They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine HClを買う | Gemcitabine HCl ic50 | Gemcitabine HCl供給者 | Gemcitabine HClを購入する | Gemcitabine HCl費用 | Gemcitabine HCl生産者 | オーダーGemcitabine HCl | Gemcitabine HCl化学構造 | Gemcitabine HCl分子量 | Gemcitabine HCl代理店
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID